Acumen Pharmaceuticals, Inc. (ABOS) — Financial statements
Income statement, balance sheet, and cash flow for Acumen Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 12 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -12 | |
| Operating Expenses | ||||||
| R&D Expenses | 105↑11.8% | 94↑121.7% | 42↑30.8% | 32↑163.0% | 12 | |
| General & Administrative Expenses | 19↓6.3% | 20↑7.4% | 19↑46.2% | 13↑76.9% | 7 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 19↓6.3% | 20↑7.4% | 19↑46.2% | 13↑76.9% | 7 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -12 | |
| Operating Expenses | 124↑8.6% | 114↑86.5% | 61↑35.2% | 45↑521.5% | 7 | |
| Total Costs & Expenses | 124↑8.6% | 114↑86.5% | 61↑35.2% | 45↑131.0% | 20 | |
| Operating Results | ||||||
| Operating Income | -124↓8.6% | -114↓86.5% | -61↓35.2% | -45↓131.0% | -20 | |
| Depreciation & Amortization | 0.18↑3.4% | 0.18↓3.3% | 0.18↑8.9% | 0.17↑4125.0% | 0.00 | |
| EBITDA | -117↓19.2% | -98↓90.1% | -52↓20.9% | -43↓118.0% | -20 | |
| EBIT | -117↓19.2% | -98↓89.7% | -52↓20.8% | -43↓118.8% | -20 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↓68.6% | 10↑0.4% | 10↑326.8% | 2↑2747.6% | 0.08 | |
| Interest Income | 7↓48.0% | 14↑32.7% | 11↑351.1% | 2↑2747.6% | 0.08 | |
| Interest Expense | 4↑3.8% | 4↑600.2% | 0.58 | 0.00 | 0.00 | |
| Non-Operating Income | -7↑57.3% | -16↓68.5% | -9↓292.6% | -2 | 0.00 | |
| Other Income / Expenses | 2↓78.6% | 12↑33.3% | 9↑268.2% | 2↑102.9% | -81 | |
| Income Before Tax | -121↓18.6% | -102↓95.4% | -52↓22.2% | -43↑57.4% | -101 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -121↓18.6% | -102↓95.4% | -52↓22.2% | -43↑57.4% | -101 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -121↓18.6% | -102↓95.4% | -52↓22.2% | -43↑57.4% | -101 | |
| Bottom-Line Net Income | -121↓18.6% | -102↓95.4% | -52↓22.2% | -43↑57.4% | -101 | |
| EPS (Basic) | -2.00↓17.0% | -1.71↓58.3% | -1.08↓1.9% | -1.06↑59.7% | -2.63 | |
| EPS (Diluted) | -2.00↓17.0% | -1.71↓58.3% | -1.08↓1.9% | -1.06↑59.7% | -2.63 | |
| Weighted Average Shares | 61↑0.9% | 60↑23.8% | 48↑19.4% | 41↑6.1% | 38 | |
| Weighted Average Diluted Shares | 61↑0.9% | 60↑23.5% | 49↑19.7% | 41↑6.1% | 38 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.